SCHEMBL17491998

SCHEMBL17491998

CC(C)(C)OC(=O)NC(COc1ccccn1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.56
PPARG P37231 5/20 0.54
ACE P12821 1/20 0.49
PPARD Q03181 2/20 0.48
IDO1 P14902 1/20 0.47
CTSS P25774 6/20 0.46
CTSK P43235 6/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
PTPN1 P18031 2/20 0.45
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491994 1.00 PPARA (0.56) PPARAPPARGACEPPARDIDO1
SCHEMBL25263868 0.89 KLK5 (0.45) PPARAPPARGACEPPARDCTSS
SCHEMBL25263870 0.89 KLK5 (0.45) PPARAPPARGACEPPARDCTSS
SCHEMBL19105154 0.83 PPARA (0.51) PPARAPPARGACEPPARDIDO1
SCHEMBL17491900 0.83 PPARA (0.62) PPARAPPARGACEPPARDIDO1
SCHEMBL4818304 0.83 PPARA (0.62) PPARAPPARGACEPPARDIDO1
SCHEMBL14057995 0.82 PPARA (0.65) PPARAPPARGACEPPARDIDO1
SCHEMBL14057991 0.82 PPARA (0.65) PPARAPPARGACEPPARDIDO1
SCHEMBL268002 0.81 ACE (0.56) PPARAPPARGACEPPARDIDO1
SCHEMBL215178 0.81 ACE (0.56) PPARAPPARGACEPPARDIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106459147-B Serine derivatives as ghrelin receptor agonists 拉夸里亚创药株式会社 2021-08-06 CN disclosed
EP-3131916-B1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC (JP) 2018-11-14 EP disclosed
US-9873695-B2 Serine derivatives as ghrelin receptor agonists RAQUALIA PHARMA INC. (JP) 2018-01-23 US disclosed
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2017-07-13 US disclosed
EP-3131916-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RaQualia Pharma Inc (JP) 2017-02-22 EP disclosed
WO-2016021191-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS GHSR, GHRHR, GIPR PPARA 911/4885PPARG 345/4885ACE 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.